A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Palovarotene (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Adverse reactions
- Sponsors Clementia Pharmaceuticals
- 14 Nov 2016 Status changed from recruiting to suspended.
- 07 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 18 Aug 2015 New trial record